ATTN: We are committed to keeping our patients informed regarding the recent cybersecurity incident involving McKesson. At this time, we are continuing to monitor the situation closely and are working to obtain the most current information available. We will provide updates as we receive additional information from McKesson and learn more about any potential impact. Thank you for your patience and trust as we navigate this situation together. CLICK HERE for more information.

Virginia Oncology Associates

Virginia Oncology Associates

Clinical Research & Trials

Cancer Center » Clinical Research & Trials » Available Trials » USO 24276
Patient Portal Cancer Resources

Listen to our podcast

RSS Feed

USO 24276

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer (TNBC) or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (TroFuse-032) MK2870-032

 

Disease Types: Breast Cancer Research

Eligibility Requirements:

• Untreated high-risk, early-stage, non-metastatic (M0) BC
• cT1c, N1-2 or cT2-T4a-d, N0-2
• Centrally confirmed TNBC or HR-low+/HER2- BC
• Bilateral tumors, multi-focal/multicentric, and inflammatory BC
are allowed, but all foci must have the same histology
• Tissue must be submitted for central confirmation of biomarkers
• No previous systemic therapy
For more information on this trial CLICK HERE .

Available at:

Virginia Oncology Associates